SCHEMBL7175658

SCHEMBL7175658

Cc1cccc(C)c1C(=O)C(C(=O)OCc1ccccc1)c1ccccc1.O=[PH3]

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 4/20 0.44
ALDH1A1 P00352 4/20 0.44
MMP8 P22894 1/20 0.43
ELANE P08246 1/20 0.41
KCNA5 P22460 1/20 0.40
CASP3 P42574 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
MAPK1 P28482 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KMT2A Q03164 1/20 0.40
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP12 P39900 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27500265 0.95 NPC1 (0.45) NPC1RAB9AL3MBTL1ALDH1A1MMP8
SCHEMBL7182786 0.91 ELANE (0.43) NPC1RAB9AL3MBTL1ALDH1A1MMP8
SCHEMBL7182128 0.90 TACR1 (0.43) NPC1RAB9AL3MBTL1ALDH1A1MMP8
SCHEMBL7174643 0.87 MMP8 (0.56) NPC1L3MBTL1MMP8TDP1KMT2A
SCHEMBL7183688 0.86 ALDH1A1 (0.39) NPC1RAB9AL3MBTL1ALDH1A1MMP8
SCHEMBL27484210 0.86 ELANE (0.43) NPC1RAB9AL3MBTL1ALDH1A1MMP8
SCHEMBL27483919 0.85 TACR1 (0.43) NPC1RAB9AL3MBTL1ALDH1A1MMP8
SCHEMBL7178274 0.85 ALDH1A1 (0.40) NPC1RAB9AL3MBTL1ALDH1A1MMP8
SCHEMBL7185317 0.84 TAAR1 (0.44) NPC1RAB9AALDH1A1ELANEKMT2A
SCHEMBL7180375 0.84 MMP8 (0.46) L3MBTL1ALDH1A1MMP8MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NPC1 772/4885RAB9A 1818/4885L3MBTL1 302/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NPC1 872/4885RAB9A 2155/4885L3MBTL1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.